Abstract: The present invention provides a system and method for converting color data from a higher color resolution to a lower color resolution. Color data is converted by first receiving a plurality of bits representing color data for an image. Next, a subset of pixels represented by the plurality of bits is selected. The color data for each pixel within the selected subset is then divided into least significant bits and most significant bits. Next, the least significant bits for each pixel within the selected subset are compared to a corresponding value in a lookup table. Finally, for each pixel within the selected subset, if the least significant bits are greater than the corresponding value in the lookup table, then the most significant bits are incremented.

Abstract: An apparatus and method of applying an effect to graphical data utilizes a graphics processor to apply the effect to a graphical image having the graphical data. To that end, the graphics processor is configured to process graphical data in accordance with a preselected graphics processing format, and the effect and graphical image are defined and converted, respectively, into the preselected graphics processing format. The graphics processor is controlled to apply the effect to the graphical image to produce an output graphical image. The output graphical image includes both the effect and the graphical image. The graphics processor may be a graphics accelerator card, and the graphics processing format may be the OPENGL™ application program interface.

Abstract: The present invention is directed to complexes consisting essentially of an isolated MHC component and an autoantigenic peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.

Abstract: This invention provides a method of inhibiting coagulation in extracorporeal circulation in a subject, comprising administration of a therapeutically effective amount of a monoclonal antibody which inhibits the ability of tissue factor to bind to factor VII/VIIa. The method prevents complex formation between tissue factor and factor VII/VIIa and thus inhibits coagulation of blood in extracorporeal procedures such as cardiopulmonary bypass and other shunt procedures. Anti-tissue factor monoclonal antibodies produced by hybridoma cell lines TFS-5G9 or TF9-6B4 may be used in the claimed methods.

Abstract: Stable forms of Taenia ovis peptide antigens, such as portions of a T. ovis oncosphere antigen which runs as a 47-52 kDa doublet, are suitable for use in vaccines to protect ruminants against infection by cestode parasites. The antigens are preferably obtained by isolation and expression of the DNA encoding them in recombinant host cells. Aspects of the invention include DNA encoding T. ovis antigens, vectors containing such DNA and host cells which express the T. ovis antigens.

Abstract: The gene encoding the TcpA pilus has been cloned. It encodes a protein useful in live, killed-cell, and synthetic vaccines. Protein production is enhanced by specific medium conditions.

Abstract: A method of isolation of a material with similar immunological properties to CA-195 from human amniotic fluid has been disclosed. This material can be substituted for CA-195 in many processes, for example in the preparation of analytical control materials.

Abstract: Substantially pure nucleic acid sequences coding for human fibrillarin have been identified and isolated. The isolated material is used to generate the protein in vitro, which is then used to identify autoimmune antibodies in patients suffering from scleroderma.

Abstract: The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.

Abstract: This invention is directed to antibodies which react with human islet amyloid polypeptide and which do not significantly react with insulin or calcitonin gene-related peptides. Preparations of antibodies are provided which bind to islet amyloid polypeptide (IAPP) which is substantially free of islet amyloid, and when isolated from humans, has the following amino acid sequence in positions 1-37:Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val- His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly- Ser-Asn-Thr-Tyr.

Abstract: The invention is directed to methods and materials useful in treating autoimmune diseases. The therapeutic agents are of the formula X--MHC--peptide or MHc--peptide--X wherein X represents a functional moiety selected from a toxin and a labeling group; MHC is an effective portion of the MHC glycoprotein, said glycoprotein dissociated from the cell surface on which it normally resides; and "peptide" represents an antigenic peptide sequence associated with an autoantigen;--represents a covalent bond or a linker bound to X and MHC or to X and peptide by covalent bonds; and--represents a covalent bond, a noncovalent association, or a linker covalently bound to or associated with the MHC and peptide. These complexes can be used to target helper T-cells which are specifically immunoreactive with autoantigens.

Abstract: Conjugates of stable nonimmunogenic polymers and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.

Abstract: The present invention is directed to complexes consisting essentially of an isolated MHC component and an autoantigenic peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.

Abstract: Bacterially synthesized polypeptides that are recognized by antibodies produced in EBV-infected humans are disclosed. Plasmids containing DNA sequences encoding portions of the EBNA and EBEA-D antigens are also disclosed, as are methods for expressing these DNA sequences in bacteria. The DNA sequence encoding the EBNA-1-related fusion polypeptide is found in a Bam H1 K-restriction fragment, while that encoding the EBEA-D-related fusion polypeptide is found in a Bam H1 M-restriction fragment.

Abstract: B cell differentiation factor which acts on B cells and participates in their differentiation into antibody-producing cells is produced by an established cell line.

Abstract: A substrate bias generating circuit including waveform shaping circuits for producing two signals having different phases on the basis of signals in phase extracted from a ring oscillator and two logic gates using these two signals having large phase difference as inputs is disclosed. A first charge pump circuit is driven with one of outputs of these two logic gates and a second charge pump circuit is driven by the other output. First charge pump circuit and second charge pump circuit are electrically coupled to generate substrate bias alternately. Since the difference in phase of two signals inputted to the two logic gates respectively is so large that a possibility is reduced of occurrence of a period in which both of input potential to charge pump circuit and input potential to charge pump circuit are at a low level even if a rise speed and a fall speed of input potential to charge pump circuit greatly differ from a fall speed and a rise speed of input potential to charge pump circuit, respectively.

Abstract: Specific and nonspecific immunomodulation, enhancement of cellular engraftment, and modulation of nonimmune cells are achieved by using various membrane-binding and soluble CD8 compositions.

Abstract: The present invention relates to a soluble form of intercellular adhesion molecule (sICAM-1) and purified and isolated human sICAM-1. This invention also relates to a purified and isolated DNA sequence encoding sICAM-1. The extracellular domain of sICAM-1 and insoluble ICAM-1 are substantially the same. ICAM-1 is involved in the process through which lymphocytes attach to cellular substrates during inflammation and serves as the major human rhinovirus receptor (HRR). sICAM-1 therefore has both the property of reducing immune inflammation and inhibiting infection of rhinovirus and Coxsackie A virus.

Abstract: Monoclonal antibodies to a 28-mer peptide present within A4-amyloid are described. These antibodies exhibit unexpected specificity for amyloid plaque structures previously unrecognized in Alzheimer's disease brains. These monoclonal antibodies are useful as reagents for use in assays and imaging of A4-amyloid in Alzheimer's disease patients.